YOLFTbeta
Kazia Therapeutics Ltd ADR

Kazia Therapeutics Ltd ADR

KZIA · NASDAQ · Healthcare / Biotechnology

6.62USD-0.33 (-4.75%)

Price History

Full chart

Market Stats

Previous Close6.95
Open6.88
Day Range6.26 – 7.00
52-Week Range4.86 – 17.40
Volume352.80K
Market Cap109.70M
P/E (TTM)0.00
Forward P/E12.82
EPS-7.62
Dividend Yield0.00%
Beta2.15
50-Day Avg12.56
200-Day Avg10.54

About

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. John Edwin Friend II, M.D.
  • Employees6
  • HeadquartersThree International Towers, Sydney, NSW, Australia, 2000, USA
  • Websitehttps://www.kaziatherapeutics.com

Leadership

  • Dr. John Edwin Friend II, M.D.Chief Executive Officer · b. 1970
  • Ms. Elissa C. Hansen ACSA, B.Com., B.Comm, FCIS, Gad Dip ACG, GAI, GAICCompany Secretary · b. 1973
  • Mr. Jeffrey BonacordaVP of Finance & Controller
  • Mr. James E. LevineChief Financial Officer · b. 1971
  • Dr. Sudha RaoChief Scientific Officer

Financials

Income Statement

Currency: AUD1999-06-302000-06-302001-06-302002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-30
Total Revenue19.32M26.75M58.91M19.59M32.93M16.35M17.61M13.50M17.31M13.28M11.15M9.91M2.02M1.51M1.07M87.00K89.00K4.07M8.79M13.11K1.56K988.11K15.18M10.00K5552.31M42.00K
Growth (%)-+38.41%+120.27%-66.74%+68.06%-50.36%+7.71%-23.30%+28.21%-23.33%-16.03%-11.12%-79.56%-25.28%-29.46%-91.85%+2.30%+4474.16%+115.87%-99.85%-88.06%+63038.02%+1436.57%-99.93%-94.45%+415755.86%-98.18%
Cost of Revenue31.76M7.11M100.82M7.59M7.17M4.72M4.65M5.45M6.95M4.09M2.52M2.22M13.07M10.25M-44.68K000000------
Gross Profit-12.43M19.64M-41.91M12.01M25.76M11.62M12.96M8.06M10.36M9.19M8.62M7.69M2.02M1.51M1.11M87.00K89.00K4.07M8.79M13.11K1.56K988.11K15.18M10.00K5552.31M42.00K
Gross Margin-64.34%73.42%-71.14%61.27%78.22%71.10%73.61%59.66%59.84%69.21%77.37%77.63%100.00%100.00%104.19%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%
Operating Expense5.69M33.29M031.01M36.26M24.01M25.13M30.36M37.38M35.02M32.40M22.92M13.46M11.19M3.15M6.49M8.23M16.84M19.64M12.50M8.38M13.18M21.56M25.41M24.12M30.77M14.26M
Operating Income-18.13M-13.66M-41.91M-19.00M-10.50M-12.39M-12.17M-22.30M-27.02M-25.83M-23.77M-15.23M-11.44M-9.68M-2.04M-6.40M-8.14M-12.77M-10.85M-12.49M-8.38M-12.20M-6.38M-25.40M-24.12M-28.46M-14.22M
Operating Margin-93.80%-51.06%-71.14%-96.97%-31.89%-75.77%-69.14%-165.16%-156.04%-194.57%-213.29%-153.69%-564.89%-639.72%-191.04%-7357.47%-9147.19%-313.71%-123.49%-95262.44%-535463.26%-1234.28%-41.99%-253990.00%-4346661.08%-1233.19%-33850.00%
EBITDA-16.78M-13.66M-42.59M-17.15M-8.62M-10.67M-11.24M-16.97M-26.04M-25.48M-23.49M-15.60M-11.36M1.33M-1.65M-5.74M-7.48M-11.72M-9.44M-10.81M-7.71M-11.11M-5.11M-23.52M-22.28M-26.59M-13.28M
EBITDA Margin-86.82%-51.06%-72.29%-87.51%-26.17%-65.30%-63.86%-125.69%-150.40%-191.91%-210.76%-157.45%-560.79%88.17%-154.84%-6600.19%-8402.10%-287.94%-107.40%-82506.87%-492715.65%-1124.32%-33.66%-235150.00%-4013885.95%-1152.21%-31626.19%
Net Income-17.08M-13.68M-42.65M-14.66M-10.41M-12.50M-12.23M-16.23M-20.00M-20.25M-18.93M-12.35M-6.50M1.31M-1.03M-7.47M-7.14M-12.06M-10.67M-6.04M-10.27M-12.47M-8.42M-25.01M-20.47M-26.78M-20.70M
Net Income Margin-88.37%-51.14%-72.39%-74.83%-31.63%-76.49%-69.47%-120.15%-115.53%-152.55%-169.80%-124.60%-320.89%86.52%-96.58%-8583.13%-8020.89%-296.29%-121.42%-46071.10%-656230.03%-1261.75%-55.46%-250140.00%-3687419.82%-1160.23%-49290.48%
R&D3.60M5.93M4.29M7.86M8.22M8.21M10.18M12.02M16.15M18.80M18.79M8.09M3.90M5.40M256.41K2.48M5.94M9.89M11.14M9.77M6.48M9.49M14.54M20.17M15.56M17.38M7.33M
R&D as % of Total Revenue18.60%22.16%7.29%40.11%24.97%50.24%57.80%88.99%93.29%141.62%168.55%81.68%192.69%357.11%24.02%2845.78%6668.94%243.04%126.72%74565.15%413801.92%960.86%95.77%201690.00%2804336.94%753.03%17442.86%
Interest Expense000344.58K0118.72K56.39K52.56K2.36K24.04K11.00K15.00K18.00K0131.70K714.52K68.62K0765.00K02.19M240.00K5.10M2.09K---
Interest Expense % of Total Revenue0.00%0.00%0.00%1.76%0.00%0.73%0.32%0.39%0.01%0.18%0.10%0.15%0.89%0.00%12.34%821.29%77.10%0.00%8.70%0.00%139808.31%24.29%33.58%20.94%---

Balance Sheet

Currency: AUD1999-06-302000-06-302001-06-302002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-30
Total Assets55.88M65.02M119.94M61.93M50.62M76.94M67.21M51.11M51.42M43.38M37.84M19.29M12.73M8.98M8.98M4.66M46.14M35.52M35.91M28.18M21.18M23.06M58.09M35.89M28.08M21.59M6.06M
Total Liabilities8.39M12.29M18.22M7.86M8.38M29.12M6.97M6.52M6.74M7.76M9.07M6.11M8.31M3.87M3.87M3.25M1.78M1.59M10.57M8.93M7.01M8.94M20.24M17.61M16.03M31.60M14.36M
Total Equity47.49M52.73M101.72M53.31M41.67M47.82M56.52M42.46M40.62M30.67M23.68M11.19M4.42M5.11M5.11M1.51M44.67M33.93M25.34M19.24M14.20M14.13M37.85M18.27M12.05M-10.02M-8.30M
Cash29.51M28.82M61.00M39.96M30.91M58.08M47.07M24.40M39.55M27.99M33.34M15.13M6.02M8.35M8.35M2.50M44.37M33.45M14.45M5.96M5.43M8.76M27.59M7.36M5.24M1.66M4.34M
Total Debt2.40M4.27M809.33K3.13M2.28M1.60M761.97K14.82K------1.42M2.71M-10.00K10.00K84.00K0--1.84M1.80M634.00K396.00K
Net Debt-27.11M-24.55M-60.19M-36.83M-28.63M-56.48M-46.31M-24.38M-39.55M-27.99M-33.34M-15.13M-6.02M-8.35M-8.35M205.06K-44.37M-33.44M-14.44M-5.87M-5.43M-8.76M-27.59M-5.52M-3.44M-1.02M-3.95M

Cash Flow

Currency: AUD1999-06-302000-06-302001-06-302002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-30
Operating Cash Flow-20.97M-18.75M-34.18M-6.68M-5.83M-10.48M-12.76M-14.44M-14.63M-20.10M-20.60M-16.61M-8.70M-7.35M-8.79M-5.71M-5.76M-11.98M-11.43M-8.66M-6.71M-8.81M-9.11M-22.76M-15.16M-9.58M-13.28M
Investing Cash Flow-4.94M-2.58M--104.80K-721.28K--754.10K-309.95K-37.73K3.73M-89.00K-10.00K287.00K6.00K171.52K-26.98K-89.68K-522.00K-7.12M150.00K2.36M-2.36M-2.36M-2.37M---
Financing Cash Flow40.75M19.95M40.16M16.08M129.12K37.05M6.10M4.04K24.90M16.95M11.56M-763.00K1.75M3.01M5.50M47.41M782.00K-17.66K3.82M3.82M12.14M28.11M3.73M12.97M5.99M15.98M
Capital Expenditure4.94M2.69M1.87M1.87M755.42K709.43K754.10K319.39K299.47K95.11K94.00K22.00K56.00K1.00K10.15K26.98K97.47K525.00K11.65K00000000
Free Cash Flow-25.92M-21.45M-36.05M-6.68M-6.59M-11.19M-13.51M-14.76M-14.92M-20.19M-20.70M-16.63M-8.76M-7.35M-8.80M-5.74M-5.86M-12.51M-11.45M-8.66M-6.71M-8.81M-9.11M-22.76M-15.16M-9.58M-13.28M
Dividends Paid----------------00000------
FCF to OCF123.57%114.37%105.48%100.00%112.96%106.77%105.91%102.21%102.05%100.47%100.46%100.13%100.64%100.01%100.12%100.47%101.69%104.38%100.10%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%
Dividend Paid to FCF----------------0.00%0.00%0.00%0.00%0.00%------

Earnings

Report DateDec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Sep 30, 2013Dec 31, 2013Feb 28, 2014Jun 30, 2014Sep 30, 2014Oct 3, 2014Feb 28, 2015Jun 30, 2015Aug 31, 2015Dec 31, 2015Feb 22, 2016Jun 30, 2016Aug 30, 2016Oct 19, 2016Feb 22, 2017Jun 30, 2017Aug 30, 2017Dec 31, 2017Feb 21, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Nov 15, 2024Jun 10, 2025Nov 7, 2025Nov 6, 2026
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00-221.00-
EPS Actual-0.32-0.08-0.080.020.020.040.04-0.01-0.01-0.10-0.09-0.12-0.12-0.06-0.05-0.06-0.06-0.03-0.03-0.09-0.07-0.04-0.19-0.09-0.05-0.130.000.01-0.05-0.04-0.04-0.02-0.02-0.03-0.03-0.03-0.03-0.02-0.02-0.01-0.01-31.22-12.30-7.64-
Surprise-------------------------------------------96.54%-
Timing-----------Pre-market--After-hoursAfter-hours-After-hours-Pre-market-Pre-market-Pre-market-After-hours-------------------

Key Statistics & Ratios

Market Cap109.70M
Enterprise Value97.76M
Trailing P/E0.00
Forward P/E12.82
PEG Ratio1.01
Price / Sales57.78
Price / Book4.45
EPS-7.62
Book Value2.92
Revenue (TTM)1.90M
Gross Profit (TTM)1.90M
EBITDA-17.84M
Profit Margin0.00%
Operating Margin-14641.04%
Return on Equity-106.90%
Return on Assets-25.71%
Shares Outstanding11.43M
Shares Float9.39M
Beta2.15
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 1 analystsTarget 28.48
  • Buy
    1

Ownership Breakdown

Institutions
28.50%
Insiders
15.42%
Retail / Other
56.08%

Top Institutional Holders

  • Bleichroeder LP
    400.00K2.57%
  • Stonepine Capital Management Llc
    345.18K2.22%
  • Point72 Asset Management, L.P.
    200.00K1.29%
  • Balyasny Asset Management LLC
    193.11K1.24%
  • F.L.Putnam Investment Management
    142.47K0.92%
  • Millennium Management LLC
    101.38K0.65%
  • Dauntless Investment Group, LLC
    79.83K0.51%
  • Cooperman Leon G
    50.00K0.32%
  • Westside Investment Management, Inc.
    47.59K0.31%
  • Royal Bank of Canada
    34.34K0.22%
  • Citadel Advisors Llc
    28.51K0.18%
  • Barclays PLC
    24.00K0.15%
  • Sequoia Financial Advisors LLC
    20.00K0.13%
  • UBS Group AG
    13.93K0.09%
  • Rockefeller Capital Management L.P.
    12.70K0.08%
  • Laird Norton Tyee Trust Co
    12.40K0.08%
  • Qube Research & Technologies
    10.61K0.07%
  • Advisor Group Holdings, Inc.
    8.74K0.06%

Top Fund Holders

  • Exemplar Growth and Income Ser FD
    143.95K1.11%
  • Fidelity Nasdaq Composite Index
    4.24K0.03%

Dividends

20131×
4.09Jan 28, 2013

Stock Splits

  • Apr 17, 20251:5
  • Oct 28, 20241:10
  • Jul 14, 20171:4
  • Jan 28, 20133038:1000
  • Jan 3, 20121:5